Eric John Snijder

Title: The Innovations of Eric John Snijder

Introduction

Eric John Snijder is a notable inventor based in Leiden, Netherlands. He has made significant contributions to the field of virology, particularly through his research on arterivirus proteins. His work has implications for understanding viral mechanisms and developing potential vaccines.

Latest Patents

Eric John Snijder holds a patent for an invention titled "Arterivirus protein and expression mechanisms." This invention provides the discovery and characterization of a novel arterivirus protein known as nsp2TF. The expression of this protein is dependent on -2 ribosomal frameshifting at a site located in the nsp2 coding region. The coding region for the unique TF domain of nsp2TF overlaps with the part of ORF1a that encodes the transmembrane region of nsp2 in arteriviruses, including PRRSV, LDV, and SHFV. Mutations affecting the expression of nsp2TF impair PRRSV replication and result in a smaller plaque phenotype. The patent also includes methods for identifying compounds that inhibit -2 frameshifting and gene expression tools for eukaryotic systems utilizing -2 frameshifting.

Career Highlights

Throughout his career, Eric John Snijder has worked with various institutions, including the South Dakota Board of Regents and Cambridge Enterprise Limited. His research has focused on the mechanisms of viral replication and the development of diagnostic methods.

Collaborations

Eric has collaborated with notable colleagues, including Ying Fang and Andrew E Firth. Their combined expertise has contributed to advancements in the understanding of arterivirus proteins.

Conclusion

Eric John Snijder's innovative work in virology, particularly regarding arterivirus proteins, showcases his significant contributions to the field. His patent and collaborations highlight the importance of research in developing diagnostic methods and potential vaccines.